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FGF8 has been shown to play important morphoregulatory roles during embryonic development. The observation that craniofacial,
cardiovascular, pharyngeal, and neural phenotypes vary with Fgf8 gene dosage suggests that FGF8 signaling induces differences in
downstream responses in a dose-dependent manner. In this study, we investigated if FGF8 plays a dose-dependent regulatory role during
embryonic submandibular salivary gland (SMG) morphogenesis. We evaluated SMG phenotypes of Fgf8 hypomorphic mice, which have
decreased Fgf8 gene function throughout embryogenesis. We also evaluated SMG phenotypes of Fgf8 conditional mutants in which Fgf8
function has been completely ablated in its expression domain in the first pharyngeal arch ectoderm from the time of arch formation. Fgf8
hypomorphs have hypoplastic SMGs, whereas conditional mutant SMGs exhibit ontogenic arrest followed by involution and are absent by
E18.5. SMG aplasia in Fgf8 ectoderm conditional mutants indicates that FGF8 signaling is essential for the morphogenesis and survival of
Pseudoglandular Stage and older SMGs. Equally important, the presence of an initial SMG bud in Fgf8 conditional mutants indicates that
initial bud formation is FGF8 independent. Mice heterozygous for either the Fgf8 null allele (Fgf8+/N) or the hypomorphic allele (Fgf8+/H)
have SMGs that are indistinguishable from wild-type (Fgf8+/+) mice which suggest that there is not only an FGF8 dose-dependent
phenotypic response, but a nonlinear, threshold-like, epistatic response as well. We also found that enhanced FGF8 signaling induced, and
abrogated FGF8 signaling decreased, SMG branching morphogenesis in vitro. Furthermore, since FGF10 and Shh expression is modulated
by Fgf8 levels, we postulated that exogenous FGF10, Shh, or FGF10 + Shh peptide supplementation in vitro would largely ‘‘rescue’’ the
abnormal SMG phenotype associated with decreased FGF8 signaling. This is as expected, though there is no synergistic effect with FGF10 +
Shh peptide supplementation. These in vitro experiments model the principle that mutations have different effects in the context of different
epigenotypes.
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The FGF family includes at least 23 members which
have been shown to induce diverse biological processes,
including cell proliferation, cell survival, branching mor-
phogenesis, and histodifferentiation. FGF function is medi-0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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to potentially activate several different signaling cascades,
including the RAS/MAPK, PLC-g, P13K, and PKC path-
ways (see reviews, Goldfarb, 2001; Ornitz and Itoh, 2002;
Sleeman et al., 2001; Szebenyi and Fallon, 1999). Fgf8 is
one of the most intensively studied members of this gene
family. FGF8/FGFR binding provides survival, mitogenic,
anti/pro-differentiation, and patterning signals during em-
bryonic development (Chi et al., 2003; Frank et al., 2002;
Garel et al., 2003; Macatee et al., 2003; Moon and Capec-
chi, 2000). FGF8 is required in gastrulation, neural pattern-
T. Jaskoll et al. / Developmental Biology 268 (2004) 457–469458ing, and left–right axis determination (Boettger et al., 1999;
Meyers and Martin, 1999; Storm et al., 2003; Sun et al.,
1999). Since Fgf8 null embryos die early in embryogenesis
(Meyers et al., 1998; Moon and Capecchi, 2000; Sun et al.,
1999), several groups have employed conditional mutagen-
esis and hypomorphic alleles to study the role of FGF8
signaling during craniofacial, cardiovascular, pharyngeal,
limb, and neural development (Abu-Issa et al., 2002; Frank
et al., 2002; Garel et al., 2003; Macatee et al., 2003; Meyers
and Martin, 1999; Meyers et al., 1998; Moon and Capecchi,
2000; Moon et al., 2000; Storm et al., 2003; Sun et al.,
2000; Trumpp et al., 1999). These studies clearly demon-
strate that FGF8 signaling plays multiple important mor-
phoregulatory roles during development. The phenotypes of
Fgf8 germline null mutants (Meyers and Martin, 1999;
Meyers et al., 1998; Moon and Capecchi, 2000) and Fgf8
hypomorphic and conditionally mutant mice (Abu-Issa et
al., 2002; Chi et al., 2003; Frank et al., 2002; Garel et al.,
2003; Lewandoski et al., 2000; Macatee et al., 2003; Moon
and Capecchi, 2000; Storm et al., 2003) indicate that in
many of its expression domains, FGF8 has unique and
required roles that cannot be compensated by other endog-
enous FGFs, and that FGF8 induces specific downstream
signal transduction pathways during embryonic develop-
ment. Moreover, since craniofacial, cardiovascular, pharyn-
geal, and neural phenotypes vary with Fgf8 gene dosage
(Abu-Issa et al., 2002; Chi et al., 2003; Frank et al., 2002;
Garel et al., 2003; Lewandoski et al., 2000; Macatee et al.,
2003; Meyers et al., 1998; Moon and Capecchi, 2000;
Storm et al., 2003), FGF8 signaling likely induces dose-
dependent differences in downstream pathways and
responses.
Embryonic submandibular salivary gland (SMG) devel-
opment is a well-studied and experimentally accessible
exemplification of embryonic epithelial branching (e.g.,
Gresik et al., 1998; Hardman et al., 1994; Hoffman et al.,
2002; Jaskoll and Melnick, 1999; Kashimata and Gresik,
1997; Kashimata et al., 2000a,b; Koyama et al., 2003;
Larsen et al., 2003; Melnick et al., 2001a,b,c; Wessells,
1977, see reviews, Jaskoll and Melnick, 2003; Melnick and
Jaskoll, 2000), and is therefore an ideal system to investi-
gate whether FGF8 regulates branching morphogenesis, and
if it does so in a dose-dependent manner.
Embryonic mouse SMG morphogenesis is initiated with
a thickening of the oral epithelium of the mandibular arch
around E11 and is best conceptualized in stages (Jaskoll and
Melnick, 1999): (1) PreBud Stage: an initial formation of
the primitive SMG knot, a thickening of the oral epithelium
adjacent to the developing tongue; (2) Initial Bud Stage:
primitive oral cavity epithelium adjacent to the developing
tongue grows down into compact neural-crest derived
mesenchyme to form a solid, elongated epithelial stalk
terminating in a bulb; (3) Pseudoglandular Stage: the solid
cord of epithelium elongates and grows by repeated end-bud
branching into the surrounding mesenchyme; (4) Canaliza-
tion Stage: the number of lobes is increased, the presump-tive ducts begin to exhibit distinct lumina lined by cuboidal
epithelial cells, the mesenchyme is more loosely packed;
and (5) Terminal Bud Stage: distinct, well-developed lumina
are seen in presumptive ducts and terminal buds (presump-
tive acini). Epithelial cell proliferation is found in all stages,
even after well-defined lumen formation in the Terminal
Bud Stage. By contrast, epithelial apoptosis begins with the
onset of lumen formation in the Canalicular Stage.
It has become increasingly apparent that morphogenesis
of complex organs such as the SMG requires cooperation
and coordination of multiple signaling pathways to regulate
cell proliferation, quiescence, apoptosis, and histodifferen-
tiation (Davidson et al., 2002, 2003; Gardner et al., 2003;
Melnick et al., 2001b). Functional studies by us and others
demonstrate that embryonic SMG epithelial cell prolifera-
tion, apoptosis, and histodifferentiation are mediated by
specific growth factors and cytokines (e.g., TGFa/EGF,
TGF-h, FGF10, TNF, IL-6, Eda, Shh) expressed at specific
times and locations (Hardman et al., 1994; Hoffman et al.,
2002; Jaskoll and Melnick, 1999, in press; Jaskoll et al.,
2002, 2003, 2004; Kashimata and Gresik, 1997; Kashimata
et al., 2000a,b; Melnick et al., 2001a,b,c; Ohuchi et al.,
2000). However, it is also clear that other signaling path-
ways play key roles during SMG morphogenesis.
One of the best candidates is the FGF8 signal transduc-
tion pathway, shown to be essential for craniofacial, neural,
and cardiovascular development (Abu-Issa et al., 2002;
Frank et al., 2002; Garel et al., 2003; Macatee et al.,
2003; Meyers and Martin, 1999; Meyers et al., 1998; Moon
and Capecchi, 2000; Moon et al., 2000; Storm et al., 2003;
Sun et al., 2000; Trumpp et al., 1999). Since (1) embryonic
SMGs are derived from mandibular epithelia in the first
pharyngeal arch (see review, Jaskoll and Melnick, 2003), (2)
Fgf8 hypomorphic and conditional mutant mice have se-
verely malformed mandibles (Abu-Issa et al., 2002; Frank et
al., 2002; Macatee et al., 2003; Trumpp et al., 1999), (3)
FGF8 signaling is critical for tooth morphogenesis in the
first pharyngeal arch (Trumpp et al., 1999; Tucker et al.,
1999), and (4) FGF8 and its cognate receptor are present in
all stages of embryonic SMG ontogeny (Jaskoll et al.,
2002), we postulated that FGF8 signaling plays an impor-
tant organogenetic role. Additionally, we observed hypo-
plastic SMGs in Fgfr2-IIIc mutant mice (Jaskoll et al.,
2002), which appears to be the primary FGF8 receptor in
the embryonic SMG (Jaskoll et al., 2002). Since mandibular
phenotypes in mouse mutants vary markedly with Fgf8
dosage, we further postulated that FGF8 regulates embry-
onic SMG development in a dose-dependent manner.
To address these hypotheses, we evaluated SMG devel-
opment in Fgf8 hypomorphic and tissue-specific ablated
mutant mice and demonstrated genotype-specific differen-
ces in SMG phenotype. In a complementary set of in vitro
experiments, we determined that enhanced FGF8 signaling
significantly induces, and abrogated FGF8 signaling signif-
icantly reduces, SMG branching morphogenesis in vitro.
Finally, since FGF10 and Shh are downstream of the FGF8
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reduced FGF8 signaling in vitro with exogenous FGF10
and/or Shh peptide supplementation. Our observation that
enhanced FGF10, Shh or FGF10 + Shh signaling incom-
pletely restored branching morphogenesis toward normal
indicates that the FGF8 signal transduction pathway induces
other specific downstream signaling responses that are
essential for embryonic SMG development.Materials and methods
Characterization of Fgf8 mutant mouse SMGs
Fgf8 wild-type and mutant mice were generated using
the strategy previously described (Frank et al., 2002; Mac-
atee et al., 2003; Moon and Capecchi, 2000) and their
genotypes were confirmed by PCR as previously described
(Frank et al., 2002; Moon and Capecchi, 2000). Fig. 1
demonstrates the different alleles used in this study: the
Fgf8H hypomorphic allele (Fig. 1A), the Fgf8C nonhypo-
morphic conditional reporter allele (Fig. 1B), Cre-mediated
recombination of the Fgf8C allele to the Fgf8CR allele (Fig.
1C), and the Fgf8N null allele (Fig. 1D). Cre-mediated
recombination of the Fgf8C allele to the Fgf8CR allele
deletes exon 5 and prevents the production of functional
Fgf8 mRNA. All mutant embryos are in a 75% C57Bl6,
25% SV129 background. Complete characterization of these
alleles is previously described (Frank et al., 2002; Macatee
et al., 2003).
The AP2a-IRESCre driver was constructed by targeting
an IRESCre cassette into the 3V untranslated region of theFig. 1. The different Fgf8 alleles. (A) The Fgf8H hypomorphic allele. (B) T
recombination of the Fgf8C allele to the Fgf8CR allele. (D) The Fgf8N null allele.AP2a locus (Macatee et al., 2003). This cassette contains an
Internal Ribosomal Entry Site, IRES (Jackson et al., 1990;
Jang and Wimmer, 1990), upstream of the Cre recombinase
gene (Sauer and Henderson, 1988) and an frt-flanked
neomycin phosphotransferase gene. Placing the IRESCre
cassette between the stop codon and the endogenous poly-
adenylation signal allows regulated production of Cre by the
AP2a locus without interfering with endogenous AP2a
function. Complete characterization of the function of this
Cre driver is detailed in Macatee et al. (2003). This allele
was used to drive recombination/inactivation of the non-
hypomorphic Fgf8AP allele in the conditional mutant mice
so that FGF8 is completely ablated from the first pharyngeal
arch ectoderm from the time of formation of the first arch
(Macatee et al., 2003).
Fgf8 wild-type and mutant pregnant females were
euthanized by cervical dislocation on days 13.5, 15.5, and
18.5 of gestation, the embryos were dissected in cold
phosphate-buffered saline (PBS), and the heads were dis-
sected. Tissues were placed in Carnoy’s fixative, and
embedded in paraplast as previously described (Jaskoll
and Melnick, 1999). Serial coronal sections were mounted
on gelatin-coated slides and stained with hematoxylin and
eosin as previously described (Jaskoll and Melnick, 1999).
A minimum of three heads per age for each genotype was
analyzed.
Culture system
Timed-pregnant females (strain C57BL/6) were obtained
from Harlan (Indianapolis, IN). Embryos were dissected in
cold PBS, staged according to Theiler (1989), and E13he Fgf8C nonhypomorphic conditional reporter allele. (C) Cre-mediated
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using a modified Trowell method as previously described
(Melnick et al., 2001a). The medium consisted of BGJb
(Life Technologies, Rockville, MD) supplemented with 1%
BSA, 0.5 mg ascorbic acid/ml, and 50 units penicillin/
streptomycin (Life Technologies), pH 7.2, and replicate
cultures were changed every other day. Supplementation
studies: paired E13 SMG primordia were cultured for 3
days in the absence or presence of exogenous FGF8 peptide
(200 ng/ml, R&D Systems, Inc.); controls consisted of
enriched BGJb alone. Interruption studies: paired E13
SMG primordial were cultured for 3 days in the presence
of soluble FGFR2-IIIc-Fc chimera (3 or 5 ng/ml; R&D
Systems); controls consisted of primordium cultured in
IgG-Fc (3 or 5 ng/ml; R&D Systems). Because a notable
difference in SMG epithelial branch number is seen be-
tween embryos within a given litter and among litters, we
calculated the Spooner branch ratios (epithelial bud number
on day 3/bud number on day 0) for each explant as
previously described (Jaskoll et al., 1994, 2003) and com-
pared the Spooner branch ratios in right and left glands
(treated and control) from each embryo. Mean Spooner
ratios were determined, the data were arcsin transformed to
insure normality and homoscedasticity, and compared by
paired t test for all embryos studied (Sokal and Rohlf,
1981). In this set of experiments, three to five explants/
treatment were analyzed.
Rescue experiments
Paired E13 SMG primordia were cultured in 5 ng/ml
FGFR2-IIIc-Fc chimera for an initial period of 3 h and then
each pair was cultured in FGFR2-IIIc-Fc or FGFR2-IIIc-Fc
+ 200 ng/ml FGF10 (R&D Systems) for 3 days (n = 8). This
FGF10 concentration has been shown in our laboratory to
induce a significant increase in branching morphogenesis in
E13 + 3 SMGs compared to controls (unpublished). A
second set of paired E13 primordia was cultured in 5 ng/
ml FGFR2-IIIC-Fc or FGFR2-IIIc-Fc + 2.5 Ag/ml Shh
peptide (R&D Systems) (n = 4). This Shh concentration
has been shown to induce a significant increase in branching
morphogenesis in E13 + 3 SMGs compared to controls
(Jaskoll et al., 2004). A third set of paired E13 primordia
was cultured in 5 ng/ml FGFR2-IIIC-Fc or FGFR2-IIIc-Fc +
200 ng/ml FGF10 + 2.5 Ag/ml Shh peptide (n = 7). A
separate set of primordial was set as controls to verify that
FGFR2-IIIc-Fc interrupted branching morphogenesis; these
controls consisted of E13 primordia cultured in 5 ng/ml
IgG-Fc for 3 days (n =6). The explants were collected and
mean Spooner ratios determined and compared as described
above.
FGF10 and Shh protein expression
FGF10 and Shh protein expression was analyzed in
E15.5 control and conditional mutant SMGs by immuno-histochemistry using anti-FGF10 and anti-Shh polyclonal
antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA)
essentially as previously described (Jaskoll et al., 2002,
2004).Results
Fgf8 gene dosage and salivary gland branching
To delineate the role of FGF8 signaling during embry-
onic SMG morphogenesis, we initially investigated the
SMG phenotype in Fgf8 hypomorphic and conditional
mutant mice. Compound heterozygous mice bearing both
the Fgf8 H and Fgf8N alleles (genotype Fgf8H/N, Abu-Issa et
al., 2002; Frank et al., 2002; Moon and Capecchi, 2000) are
hypomorphs; they produce less than 50% the amount of
Fgf8 mRNA of wild-type animals (Frank et al., 2002); they
are small and exhibit craniofacial abnormalities such as
micrognathia and cleft palate, central nervous system mal-
formations, and a host of other congenital defects (Abu-Issa
et al., 2002; Frank et al., 2002). The tissue-restricted,
conditional mutant mice used in this study are also com-
pound heterozygotes at the Fgf8 locus; they bear a non-
hypomorphic conditional allele called Fgf8C , and the Fgf8N
allele. They also carry the Cre-recombinase driver, AP2a-
IRESCre, in which Cre recombinase coding sequences are
expressed under control of the AP2a gene; this Cre driver
inactivates the Fgf8 conditional allele in the ectoderm of the
first pharyngeal arch from the time of arch formation
(Macatee et al., 2003). The genotype of these animals is
Fgf8C/N; AP2a IRESCre/+. These conditional mutants display
an array of severe craniofacial, cardiovascular, and glandu-
lar abnormalities, including a severely hypoplastic mandible
(Macatee et al., 2003).
We analyzed E13.5, E15.5, and E18.5 Fgf8 control
(Fgf8+/+ or Fgf8C/+), hypomorphs (Fgf8H/N), and condi-
tional mutant (Fgf8C/N; AP2aIRESCre/+) SMGs. These pha-
ryngeal arch, Fgf8 ectoderm-ablated mutants will
henceforth be referred to as Fgf8 conditional mutants
(CM). The E13.5 control SMG appears as an elongated
solid cord of epithelium terminating in an end-bulb con-
sisting of several branches (i.e., a Late Initial Bud Stage)
(Figs. 2A, D). In contrast, the E13.5 Fgf8 hypomorphs
exhibit a hypoplastic, branchless SMG bud (compare Figs.
2B, E to 2A, D) which is similar in appearance to an
earlier Initial Bud Stage (Jaskoll and Melnick, 1999). The
E13.5 Fgf8 conditional mutant SMG is severely hypoplas-
tic (compare Figs. 2C, F to 2A, D), consisting of an
extremely small, branchless initial bud similar to the
earliest Initial Bud Stage (Jaskoll and Melnick, 1999).
Interestingly, in all E13.5 conditional mutants analyzed
(5/5), the SMG buds laterally from the epithelium instead
of ventrally (compare Figs. 2C, F to 1A, D); this abnormal
SMG positioning is also frequently (3/5) seen in Fgf8
hypomorphs (Figs. 2B, E).
Fig. 2. Abnormal SMG phenotypes in E13.5 Fgf8 hypomorphic and conditional mutants. (A) E13.5 Fgf8 control SMG bud. (B) E13.5 Fgf8 hypomorphic
mutant SMG buds (arrows). (C) E13.5 Fgf8 conditional mutant SMG buds (arrows). (D–F) Higher magnifications of control (D), hypomorphic (E), and
conditional mutant (F) SMGs. In the control mouse (A, D), Late Initial Bud Stage SMGs (S) with branches in the end-bulb epithelium are seen in the mandible
ventrolateral to the tongue (T). The Fgf8 hypomorphic SMG (B, E) is small and exhibits no branches. In contrast, the conditional mutant gland (C, F) consists
of an extremely small epithelial bud composed of disorganized cells. These conditional mutant glands bud laterally from the oral epithelium; this abnormal bud
position is also frequently seen in hypomorphic mutants (see right gland in B and E). Coronal sections of control and mutant heads are shown. Bar, A–C, 50
Am; D–F, 25 Am.
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proliferation and branching morphogenesis occurs, so that
by E15.5, the SMG is characterized by extensive epithelial
branching and early ductal luminization (Canalicular Stage)
(Fig. 3A). The hypomorphic gland undergoes branching but
only progresses to the Early Pseudoglandular Stage (Fig.
3B); these glands are hypoplastic compared to controls,Fig. 3. SMG hypoplasia and aplasia in Fgf8 hypomorphic and conditional mutant m
Fgf8 hypomorphic (HYPO) SMG. (C) E15.5 Fgf8 conditional mutant (CM) SMG.
extensive epithelial branches and presumptive ductal lumina (arrow heads) are se
ductal lumina (an Early Pseudoglandular Stage SMG). The Fgf8 conditional mut
like’’ morphology. (D–F) E18.5 SMGs. (D) E18.5 Fgf8 control mice exhibit Late
distinct lumina. (E) E18.5 hypomorphic mutant SMGs are characterized by fewe
Terminal Bud Stage SMG). (F) No SMGs are seen in E18.5 Fgf8 conditional mu
occupied by the SMG. SM, submandibular gland; SL, sublingual gland. Bar: A adisplaying fewer branches and no ductal lumina (compare
Figs. 3B to A). Interestingly, the conditional mutant gland
has failed to progress beyond its Early Initial Bud Stage and
presents as a single, small epithelial bud (Fig. 3C). This
severely abnormal phenotype indicates that branching mor-
phogenesis did not occur in the complete absence of FGF8
in the oral epithelium.ice. (A–C) E15.5 SMGs. (A) E15.5 Fgf8 control (CONT) SMG. (B) E15.5
The E15.5 control SMG (A) is at the Canalicular Stage, the stage at which
en. The Fgf8 hypomorphic SMG (B) is small, with fewer branches and no
ant SMG (C) remains as a single epithelial bud and retains its ‘‘initial-bud-
Terminal Bud Stage SMGs consisting of ducts and terminal buds displaying
r terminal buds displaying small or absent lumina (Late Canalicular/Early
tant mice; rather, undifferentiated muscle (*) is found in the site normally
nd B, 50 Am; C, 30 Am; D–F, 50 Am.
T. Jaskoll et al. / Developmental Biology 268 (2004) 457–469462By E18.5, the control SMG has achieved the Terminal
Bud Stage, the stage at which distinct, well-developed
lumina are seen in presumptive ducts and proacini (Fig.
3D). The hypomorphic gland retains its hypoplastic
phenotype; it is characterized by decreased branching
morphogenesis and smaller lumina compared to control
glands (compare Figs. 3E to D). Surprisingly, no SMGs
are found in E18.5 conditional mutants (24/24) (Fig. 3F);
instead we detect undifferentiated muscle in the sites
normally occupied by the SMG. Our observation ofFig. 4. Fgf8 gene-dosage and phenotypic effect. (A) Normal branching morpho
heterozygous (+/H or +/N) mice which express Fgf8 transcript amounts greater t
hypomorphic (HYPO; Fgf8H/N) mice to less than 50% of wild-type mice results i
glands. The absence of Fgf8 mRNA in first arch ectoderm in conditional mutants (C
E13.5 and E15.5 SMGs and, on day 18.5, SMG aplasia. (B) A graphical represent
Fgf8 gene dosage and the evolving epigenome.hypoplasia and aplasia in E18.5 Fgf8 hypomorph and
conditional mutants, respectively, indicate that FGF8
signaling is essential for branching morphogenesis and
epithelial cell survival during later stages of SMG
development.
Finally, to determine if a lesser reduction in Fgf8 expres-
sion affects embryonic SMGmorphogenesis, we investigated
the SMGphenotype in 18.5Fgf8+/H andFgf8+/Nmutant mice.
These mice express progressively decreasing amounts of
functional Fgf8 mRNA (Frank et al., 2002). They are indis-genesis is seen in E13.5, E15.5, and E18.5 wild-type (+/+) mice and in
han or equal to 50% seen in wild-type mice. Reduction of Fgf8 mRNA in
n no branching in E13.5 SMGs and reduced branching in E15.5 and E18.5
M; Fgf8C/N; AP2aIRESCre/+) results in no SMG branching morphogenesis in
ation of the phenotypic surface that derives from the interaction of declining
T. Jaskoll et al. / Developmental Biology 268 (2004) 457–469 463tinguishable from wild-type mice throughout development
(Moon and Capecchi, 2000; Anne Moon, unpublished data)
and both Fgf8+/N and Fgf8+/H SMGs are normal (data not
shown).
Taken together, our data indicate that there is a dose-
dependent phenotypic response (Fig. 4A). Heterozygous
mice with Fgf8 transcript levels equal to or greater than
50% of wild-type mice (Frank et al., 2002) exhibit
normal branching morphogenesis in E13.5, E15.5, and
E18.5 SMGs. By contrast, an expression of Fgf8 tran-
script levels at less than 50% of wild-type mice, as seen
in hypomorphs (Frank et al., 2002), results in no
branching morphogenesis in E13.5 SMGs and reduced
branching morphogenesis in E15.5 and older SMGs.
Finally, the absence of Fgf8 expression in the ectoderm
of the first pharyngeal arch of conditional mutant (CM)
mice (Macatee et al., 2003) results in no branching
morphogenesis in E13.5 and E15.5 SMGs and SMG
aplasia in E18.5.
Epithelial branching is a multifactorial trait, largely
dependent upon a series of interrelated genetic circuits
through which morphogenesis is realized (i.e., its epige-
notype). The functional epigenome changes with advanc-
ing gestational age. A phenotypic surface in three-
dimensional state space can be utilized to visualize the
interaction of variable single gene dosage within an
evolving epigenetic context (see review, Nijhout, 2003).
A ‘‘first pass’’ graphical visualization of the Fgf8-associ-
ated phenotypic landscape is depicted in Fig. 4B. Semi-
quantitative estimates of branching and gene dosage were
derived from the experimental data explicated above.
These variable relationships display a trend which isFig. 5. Enhanced or abrogated FGF8 signaling modulates embryonic SMG branc
SMG primordia were cultured for 3 days in the absence (A) or presence (B) of 200
increase in bud number compared to controls. (C, D) Abrogated FGF8 signaling.
(Control) or (D) FGFR2-IIIc-Fc (R2-Fc). FGFR2-IIIc-Fc supplementation resulted
Bar, 75 Am. (E) A comparative representation of the percent change in Spooner bra
minimum of three explants/treatment were evaluated.approximately described by a second-order polynomial
model with two independent variables
z ¼ 1:57 þ ð0:299xÞ þ ð0:301yÞ þ ð0:003xyÞ
þ ð0:088x2Þ þ ð0:009y2Þ
where z is the dependent variable, branching, and x and y
are the independent variables, gene dosage and gestational
age, respectively. The shape of the phenotypic surface
(Fig. 4B) reveals that Fgf8 loss of function is ultimately
epistatic to the epigenome under normal physiologic con-
ditions (i.e., no other gene mutations nor untoward envi-
ronments). The epistasis of declining Fgf8 function is a
nonlinear emergent property of the complete epigenotype.
Enhanced and abrogated FGF8 signaling in vitro
To further investigate the functional role of FGF8, we
used our well-defined organ culture system (Jaskoll et al.,
1994, 2003, 2004; Melnick et al., 2001a,b,c) to analyze the
effect of enhanced or decreased FGF8 signaling on embry-
onic SMG development. Paired E13 (Late Initial Bud Stage)
SMG primordia were cultured in the absence or presence of
200 ng/ml FGF8 peptide for 3 days. Exogenous FGF8
peptide supplementation induced a significantf36% (P <
0.05) increase in branching (Spooner ratios) compared to
controls (Figs. 5A, B, E).
We then conducted in vitro interruption studies. Al-
though alternate-spliced forms of FGF8 have been shown
to bind with high affinity to FGFR2-IIIc, FGFR3-IIIc, and
FGFR4 (MacArthur et al., 1995; Ornitz, 2000), the absencehing morphogenesis in vitro. (A, B) Enhanced FGF8 signaling. Paired E13
ng/ml FGF8 supplementation. FGF8 supplementation induced a significant
Paired E13 SMG primordia were cultured for 3 days in (C) 5 ng/ml IgG-Fc
in a significant decline in branching morphogenesis compared to control.
nching ratios associated with different treatments relative to each control. A
T. Jaskoll et al. / Developmental Biology 268 (2004) 457–469464of FGFR3 and FGFR4 at critical stages of SMG develop-
ment (Jaskoll et al., 2002) indicates that FGF8 likely trans-
mits its signal through FGFR2-IIIc. Thus, we interrupted
FGF8 signaling by adding exogenous soluble FGFR2-IIIc-
Fc chimera to the culture medium to competitively bind
endogenous FGFR2-IIIc ligands; controls consisted of IgG-
Fc supplementation. This exogenous receptor/ligand bind-
ing methodology has previously been used successfully to
interrupt FGFR2 signaling (Qiao et al., 2001). E13 SMG
primordia were cultured in different concentrations of
FGFR2-IIIc-Fc chimera (3 or 5 ng/ml) or IgG-Fc (3 or 5
ng/ml) for 3 days and mean Spooner rations were deter-
mined. Treatment with exogenous FGFR2-IIIc-Fc resulted
in a significant dose-dependent decrease in Spooner branch
ratios compared to controls (Figs. 5C, D, E). Specifically, a
31% (P < 0.01) and 45% (P < 0.02) decrease in Spooner
ratios were seen in the presence of 3 and 5 ng/ml FGFR2-
IIIb-Fc chimera, respectively. These results mimic that of
the in vivo mutants reported above.
Exogenous FGF10 and/or Shh supplementation in vitro
restores the abnormal SMG phenotype toward normal
Although previous studies have demonstrated that FGF8
regulates Fgf10 and Shh expression in the developing
embryo (Frank et al., 2002; Macatee et al., 2003; Moon
and Capecchi, 2000; Moon and Reichert, unpublished), it
was uncertain if FGF8 regulates FGF10 and Shh proteinFig. 6. Fgf8 conditional mutant SMGs exhibit a marked decrease in FGF10 and Sh
(CONT) SMG. (B) E15.5 conditional mutant (CM) SMG bud. (C, D) Shh immunolo
Note that the E15.5 Fgf8 conditional mutant SMG appears as a small, single, primexpression in embryonic SMGs. Thus, we analyzed the cell-
specific distribution of FGF10 and Shh protein in E15.5
control and conditional mutant mouse SMGs. As shown in
Fig. 6, we see a notable decrease in immunodetectable
FGF10 and Shh protein in E15.5 Fgf8 conditional mutant
SMGs compared to controls. These results indicate that
FGF8 regulates FGF10 and Shh protein expression in the
developing SMGs as well.
We then postulated that the abnormal SMG phenotypes
of Fgf8 hypomorphs and conditional mutants result, at
least in part, from perturbation of downstream signaling
pathways involving FGF10 and/or Shh. To test this hy-
pothesis, we conducted a series of in vitro rescue experi-
ments. We first focused on FGF10 since FGF10 signaling
has been shown to play a critical morphoregulatory role
during embryonic SMG development (Ohuchi et al., 2000;
Revest et al., 2001). Paired E13 SMG primordia were
initially cultured in 5 ng/ml FGFR2-IIIc-Fc for 3 h, and
then the paired explants were cultured in 5 ng/ml FGFR2-
IIIc Fc, with or without 200 ng/ml FGF10 peptide, for 3
days; controls consisted of E13 SMG primordia cultured in
5 ng/ml IgG Fc. Spooner ratios were determined and
differences analyzed by paired t test. FGF10 supplemen-
tation induced a significant 58% (P < 0.05) increase in
branching compared to FGFR2-IIIc-Fc treatment alone
(Figs. 7A, B, G).
We then sought to use exogenous Shh peptide supple-
mentation to rescue the abnormal SMG phenotype associ-h protein expression. (A, B) FGF10 immunolocalization: (A) E15.5 control
calization: (C) E15.5 control SMG. (D) E15.5 conditional mutant SMG bud.
itive epithelial primordium budding laterally (B, D). T, tongue. Bar, 50 Am.
Fig. 7. FGF10 and/or Shh peptide supplementation in vitro restores branching morphogenesis toward normal. Paired E13 embryonic SMGs were initially
incubated for 3 h in FGFR2-IIIc-Fc chimera and then cultured for 3 days in FGFR2-IIIc-Fc (A, C, E), FGFR2-IIIc-Fc + 200 mg/ml FGF10 (B), FGFR2-IIIc-Fc
+ 2.5 Ag/ml Shh (D), or FGFR2-IIIc-Fc + 200 mg/ml FGF10 + 2.5 Ag/ml Shh (F). Representative control and treated explants are shown for each set of
experiments. Bar, 75 Am. (E) A comparative representation of the percent branching restoration associated with different treatments relative to each control. R2
= FGFR2-IIIc-Fc. FGF10 rescue: n = 8; Shh rescue: n = 4; FGF10 + Shh rescue: n = 7 and IgG-Fc controls, n = 6.
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shown to play an essential role during embryonic SMG
development (Jaskoll et al., 2004). Paired E13 primordia
were cultured in 5 ng/ml FGFR2-IIIc-Fc, with or without
2.5 Ag/ml Shh peptide, for 3 days as described above. Shh-
supplemented explants exhibit a significant 44% (P < 0.05)
increase in branching morphogenesis compared to FGFR2-
IIIc-Fc treatment alone (Figs. 7C, D, G). Shh-supplemented
explants do not significantly differ from FGF10-supple-
mented explants (P > 0.5).
Finally, to determine if FGF10 and Shh act synergisti-
cally, we attempted to rescue the SMG phenotype with
abrogated FGF8 signaling with a combination of exogenous
FGF10 + Shh peptide supplementation. Paired E13 primor-
dia were cultured in 5 ng/ml FGFR2-IIIc-Fc, with or without
200 ng/ml FGF10 + 2.5 Ag/ml Shh as described above.
Combined FGF10 + Shh supplementation induced a signif-
icant 68% (P < 0.001) increase in branching morphogenesis
compared to FGFR2-IIIc-Fc treatment alone (Figs. 7E, F,
G). Interestingly, the combined FGF10 + Shh peptide
supplementation was no more effective than FGF10 peptide
supplementation alone (P > 0.5) or Shh peptide supplemen-
tation alone (P > 0.2). Thus, there appears to be no
synergism between FGF10 and Shh.
It is important to note that exogenous FGF10 or Shh
peptide supplementation significantly restored branching to84% or 76% of the level seen in controls, respectively.
Combined FGF10 + Shh supplementation restored branch-
ing to about 89% of control. This incomplete compensation
for decreased FGF8 signaling suggests that FGF8 signaling
induces additional critical and specific downstream path-
ways during SMG organogenesis.Discussion
It is well established that members of the FGF family
play key roles during embryogenesis as they mediate cell
proliferation, survival, and/or apoptosis (see reviews, Gold-
farb, 2001; Ornitz and Itoh, 2002). Recent studies of mice
with FGF8 reduction or conditional inactivation during
murine development have shown that FGF8 signaling is
essential for the development of the face and mandible,
cardiovascular and nervous systems, and pharyngeal arch-
derived structures such as the thymus and parathyroids
(Abu-Issa et al., 2002; Chi et al., 2003; Frank et al., 2002;
Garel et al., 2003; Macatee et al., 2003; Storm et al., 2003).
Of particular interest is the observation that FGF8 regu-
lates mandibular morphogenesis in a dose-dependent man-
ner. The complete ablation of FGF8 in mandibular arch
epithelia in Fgf8 conditional mutants results in more severe
craniofacial malformation than seen in the hypomorphic
T. Jaskoll et al. / Developmental Biology 268 (2004) 457–469466mouse. The availability of these Fgf8 hypomorphic and
conditional mutant mice provide an opportunity to begin to
dissect the relative role of Fgf8 gene dosage during salivary
gland (SMG) morphogenesis.
In this study, we investigated the SMG phenotype in
Fgf8 hypomorphic and conditional mutants with progres-
sive development. Our results indicate that FGF8 signaling
is essential for normal embryonic SMG development and
that the extent of its development is dependent on Fgf8
gene dosage. We found that SMG development is unaf-
fected in Fgf8 mutants heterozygous for the null (Fgf8+/N)
or hypomorphic (Fgf8H/+) allele which have been shown
to express decreased levels of Fgf8 transcript compared to
control (Frank et al., 2002; Moon and Capecchi, 2000).
However, a reduction of Fgf8 expression in hypomorphic
(Fgf8H/N) mutants to less than 50% of wild-type mice
(Frank et al., 2002) results in a hypoplastic gland. Impor-
tantly, the complete elimination of Fgf8 expression from
first pharyngeal arch (mandibular) ectoderm in conditional
mutants (Fgf8C/N; AP2aIRESCre/+) results in early ontogenic
arrest, involution and absence of the SMGs by E18.5.
Thus, a Fgf8 gene dosage effect on embryonic SMG
development is clearly demonstrated in this study (summa-
rized in Fig. 4A). Similar Fgf8 dose-dependent effects on
midbrain and cerebellar morphogenesis were seen in E17.5
Fgf8 knockdown and tissue-specific knockout mice (Chi et
al., 2003). Deletion of midbrain and cerebellar structures
increased in severity with further progressive loss of Fgf8
function, culminating in the absence of these neural struc-
tures with the complete elimination of Fgf8 function in
conditional null mutants.
SMG hypoplasia and aplasia in E18.5 Fgf8 hypomorphic
and conditional mutants, respectively, indicates that FGF8
signaling plays an important morphoregulatory and prosur-
vival role during embryonic SMG morphogenesis. Specif-
ically, the absence of SMGs in E18.5 Fgf8 conditional
mutant mice indicates that FGF8 signaling is essential for
initial epithelial branching and for subsequent Pseudogland-
ular Stage and older SMG development. The functional
presence of endogenous levels of other FGF/FGFR signal-
ing pathways (e.g., FGF10/FGFR2-IIIb) and other parallel
pathways (e.g., EGF/EGFR, IGF-II/IGF-1R) could not pre-
vent the hypoplastic development of hypomorphic SMGs
nor the complete death of embryonic SMG cells in the Fgf8
conditional mutants. Equally important, the presence of an
initial SMG bud in Fgf8 conditional mutants indicates that
FGF8 signal transduction is not required for early initial bud
formation.
FGF signaling potentially activates several key path-
ways, including the RAS/MAPK, PLC-g, and P13 kinase
(P13K) pathways (see reviews, Boilly et al., 2000; Jaskoll
and Melnick, in press; Ornitz, 2000; Ornitz and Itoh, 2002;
Powers et al., 2000). The components of the PLC-g, P13K,
and PKC signaling pathways are found in all stages of
embryonic SMG development (Koyama et al., 2003; Larsen
et al., 2003). Moreover, inhibition of RAS/MAPK or P13Ksignaling significantly reduced SMG branching morphogen-
esis in vitro (Kashimata et al., 2000a; Koyama et al., 2003;
Larsen et al., 2003), whereas inhibition of PKC modestly
increased branching (Koyama et al., 2003). Although the
importance of the RAS/MAPK, P13K, PLC-g, and PKC
during embryonic SMG branching morphogenesis has been
demonstrated, it is presently unclear which signaling cas-
cades are specifically downstream of the FGF8 signal
during embryonic SMG development. Our demonstration
of a marked decrease in epithelial branching in Fgf8
hypomorphic and conditional mutant mice, as well as the
dose-dependent downregulation of epithelial branching
morphogenesis in vitro, suggest that FGF8 acts as a mito-
genic factor during embryonic SMG branching morphogen-
esis and epithelial cell proliferation. Furthermore, our
observation of SMG aplasia in E18.5 conditional null
mutants indicates that FGF8 also acts as a survival factor
during later stages of development. Future studies are
needed to fully delineate which pathways are downstream
of the FGF8 signaling pathway at various stages of embry-
onic SMG development.
Nevertheless, previous studies have demonstrated that
Fgf10 and Shh expression are altered by modulated FGF8
signaling (Aoto et al., 2002; Frank et al., 2002; Moon and
Capecchi, 2000). Here we show that abrogated FGF8
signaling downregulates FGF10 and Shh protein expression
in the developing embryonic SMG. Knowing that both
FGF10 and Shh signaling play critical morphoregulatory
roles during embryonic SMG branching development (Jas-
koll et al., 2004; Ohuchi et al., 2000; Revest et al., 2001),
we postulated that exogenous FGF10 and/or Shh peptide
supplementation could restore branching morphogenesis to
the normal level. Using soluble FGFR2-IIIc-Fc chimera to
bind endogenous FGF8 ligand, we designed in vitro FGF8
abrogation studies which could then be used to assess if
FGF10 and/or Shh peptide supplementation could restore
branching morphogenesis to the level seen in control glands
(Fig. 7).
For several reasons, we had previously concluded that
abnormal SMGs in Fgfr2-IIIc mutant mice are due to
decreased FGF8/FGFR2-IIIc signaling (Jaskoll et al.,
2002). First, although FGF8 isoforms have been shown to
bind with high affinity to FGFR2-IIIc, FGFR3-IIIc, or
FGFR4 (MacArthur et al., 1995; Ornitz, 2000; Ornitz et
al., 1996), the absence of FGFR3 and FGFR4 from Initial
Bud, Pseudoglandular, and Canalicular Stage SMGs indi-
cates that FGF8 likely mediates its signal through FGFR2-
IIIc (Jaskoll et al., 2002). Second, although several inves-
tigators have suggested that FGF8 signals through FGFR1,
Chellaiah et al. (1999) have clearly demonstrated that FGF8
does not bind to FGFR1. Third, although other FGFs can
also bind to FGFR2-IIIc, the absence of Fgf9 transcripts
from embryonic SMGs (Colvin et al., 1999), the normal
SMG phenotype in Fgf4 null mice (A. Moon, E.J. Park, L.
Francis, unpublished), and the relatively normal phenotype
in Fgf2 and Fgf6 null mice (Fiore et al., 1997; Miller et al.,
T. Jaskoll et al. / Developmental Biology 268 (2004) 457–469 4672000), indicates that FGF2, FGF4, FGF6, and FGF9 (the
other known FGFR2-IIIc ligands) do not appear critical to
embryonic SMG development. Consequently, if FGFR2-
IIIc-Fc disturbs SMG morphogenesis in vitro, it is primarily
because FGF8 signaling has been diminished (not because
other FGF signaling has been diminished).
As expected, variable concentrations of FGFR2-IIIc
chimera demonstrate a significant dose-dependent decrease
in branching morphogenesis. FGF10 supplementation of
FGF8 abrogated explants induced a significant increase in
SMG branching and restored the gland to 84% of normal.
This result is consistent with FGF10 peptide supplementa-
tion in vitro being able to stimulate SMG branching mor-
phogenesis (Hoffman et al., 2002; Jaskoll and Melnick,
unpublished data). The observation of SMG aplasia in
Fgf10 null (Ohuchi et al., 2000) and Fgf8 conditional
mutant mice (present study) suggests that FGF8 and
FGF10 probably elicit some of the same downstream
targets, although through different receptors (i.e., FGF8
binds to FGFR2-IIIc and FGF10 binds to FGFR2-IIIb).
Conversely, our finding that enhanced FGF10-mediated
signaling in vitro incompletely compensated for decreased
FGF8 signaling suggests that, during embryonic SMG
development, the FGF8 signal transduction pathway indu-
ces specific and unique downstream responses different
from those mediated by FGF10 signaling. There is other
evidence that different FGF receptors may mediate different
downstream signaling cascades (see reviews Boilly et al.,
2000; Goldfarb, 2001; Ornitz and Itoh, 2002; Powers et al.,
2000).
Shh supplementation of FGF8 abrogated explants also
induced a significant increase in branching morphogenesis
and restored branching morphogenesis to 76% of normal.
On the basis of this result, we again conclude that enhance-
ment of a single downstream target is insufficient to
completely compensate for decreased FGF8 signaling.
There was no synergy between FGF10 and Shh. Finally, it
is interesting that exogenous FGF8 peptide supplementation
is reciprocally able to rescue the abnormal SMG phenotype
seen with abrogated Shh signaling in vitro (Jaskoll et al.,
2004). Such is to be expected of separate, but related, motifs
in a larger genetic-regulatory network which is integrated to
form a functional module (Oltvai and Barabasi, 2002).
These ‘‘rescue experiments’’ allow us to further grasp the
advantage of deriving a quantitative mathematical model of
the phenotypic landscape related to Fgf8 gene dosage within
an epigenetic context (Fig. 4B). To be sure, the epigenome
is multidimensional, with as many orthogonal axes as there
are independent variables (Nijhout, 2003). Nevertheless,
even a simple three-dimensional model (Fig. 4B) permits
us to intuitively understand that the epistasis of declining
Fgf8 function is a nonlinear emergent property of the
complete epigenotype, and to conceptualize with some
accuracy as to how this epistasis might disappear in a
context of an altered epigenotype containing a nonphysio-
logic challenge (e.g., a simultaneous gain of functionmutation in a related gene). The in vitro rescue experiments
reported here demonstrate that increased FGF10 or Shh
signaling precludes the epistasis of decreased FGF8 signal-
ing. They model the principle that mutations have different
effects in the context of different epigenotypes (Buchner et
al., 2003; Nadeau, 2003). We have designed future in vivo
knock-out/knock-in (Fgf8/Fgf10 or Fgf8/Shh) experiments
to more fully explore this important issue.Acknowledgments
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